THE RISK OF LATE BREAST CANCER SCREENING VERSUS AXILLARY LYMPHADENOPATHY ASSOCIATED WITH COVID-19 VACCINATION

• DOI: 10.22533/at.ed.1592202218049

• Palavras-chave: Vaccina; Lymphadenopathy; Covid-19

• Keywords: Vaccina; Lymphadenopathy; Covid-19

• Abstract:

  The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted morbidity and mortality worldwide. Unilateral axillary lymphadenopathy induced by the COVID-19 vaccine is particularly relevant in women with breast cancer, with a predilection for metastasis to the axillary lymph nodes. Clinicians, radiologists, and patients may be concerned about COVID-19 vaccine-induced unilateral axillary lymphadenopathy because it may be a sign of breast cancer metastasis, leading to a diagnostic conundrum over whether to recommend a biopsy or short-term follow-up. This literature review aims to assess the best available evidence of axillary lymphadenopathy after COVID-19 vaccination. Recognizing COVID-19 vaccine-induced unilateral axillary lymphadenopathy as a potential differential diagnosis and making efforts to investigate the patient's vaccination history are crucial to avoid overestimating the burden of axillary disease and making appropriate therapeutic recommendations.

• Número de páginas: 7